Melina Claussnitzer
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Single-cell transcriptomic and proteomic technologies enable molecular profiling of immune cells at scale but provide limited access to cellular phenotypes shaped by spatial organisation, organelle architecture and cytoskeletal remodelling. Here we present TGlow, a scalable high-content imaging platform optimized for systematic single-cell phenotyping of primary human lymphocytes. TGlow integrates cyclic immunofluorescence, deep z-stack confocal imaging, and open-source data processing pipelines, including both classical and self-supervised vision transformer-based feature extraction, to jointly quantify cellular morphology, organelle organization, and immune activation states. Applied across over 400,000 primary human T cells spanning CD4 + activation time courses, drug perturbations, CRISPR knockouts and CD8 + T-cell exhaustion, TGlow resolves distinct and reproducible phenotypic states. We uncover dose-dependent and mechanism-specific drug phenotypes, such as defective endoplasmic reticulum polarisation under mycophenolic acid and tofacitinib. We show that mitochondrial clustering reveals activation– and cell-cycle–linked remodelling programs, CRISPR perturbations map gene-specific phenotypes that reposition cells along activation trajectories, and we identify a previously unrecognised collapse of cytoskeletal architecture in exhausted CD8 + T cells. TGlow provides a scalable framework for high-dimensional phenotyping of lymphocyte states advancing functional genomics, perturbation screening and population-level immune profiling by resolving the morphological and functional heterogeneity of lymphocytes and enabling systematic linkage of genetic and pharmacological perturbations to cellular function.
Year:
2026
Alzheimer’s disease (AD) is marked by hallmark neuropathological changes in the brain. However, its upstream genetic determinants, beyond the central nervous system (CNS), remain largely unexplored. To that extent, we integrated human genomic data with cross-tissue and single-cell analyses across up to 40 peripheral tissues and 100 brain regions. We observed limited genetic enrichment in the CNS, with brain-resident microglia emerging as the sole enriched cell type. Instead, AD risk loci were predominantly enriched in peripheral immune compartments and immune-enriched barrier tissues, such as the lung and the digestive tract, and particularly within myeloid-lineage cells. Leveraging gene expression profiles from peripheral immune cells, we recreated an age-related susceptibility curve for AD, identifying ages 55-60 as a critical window for immune activation linked to AD risk. Our findings position the peripheral immune system as a central contributor of disease susceptibility, opening new directions for early intervention beyond the brain.
Year:
2026
Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.
Year:
2025
The 9p21.3 locus is the strongest genetic association with coronary artery disease (CAD), yet its causal mechanisms remain unresolved. We map the regulatory architecture of 9p21.3 in disease-relevant vascular cells, identifying 12 enhancers within the CAD risk haplotype that respond dynamically to inflammatory and metabolic stress in fibroblasts and smooth muscle cells. These activated states are enriched for CAD heritability, implicating stress-responsive vascular wall cells in disease pathophysiology. Dense CRISPRi tiling integrated with fine-mapping and genomic constraint across >500,000 individuals nominates MTAP as the effector gene, with rs1537371 as a likely causal variant. Perturbation and multi-modal analyses show that MTAP loss induces pro-fibrotic and angiogenic programs and sensitizes vascular cells to TGF- β –driven pathological transitions. Our findings reveal a vascular-specific enhancer network through which noncoding variation at 9p21.3 modulates CAD risk via MTAP —a previously unrecognized regulator of vascular remodeling located 269 kb from the risk haplotype. Highlights 9p21.3 CAD risk locus harbors 12 functional enhancers active in vascular wall cell types CAD heritability is enriched in stressed vascular fibroblasts and smooth muscle cells High-resolution CRISPRi-MAC-seq maps 9p21.3 enhancer-gene and SNP-gene interactions MTAP identified as a causal effector gene regulated by 9p21.3 fine-mapped and constrained variants MTAP modulates TGF-β-driven pathological vascular cell transitions
Year:
2025
Peroxisome proliferator-activated receptor γ (PPARγ) is the master regulator of adipogenesis, but the mechanisms underlying its strong induction in response to adipogenic cues are poorly understood. Using human mesenchymal stem cells as a model system, we show that the PPARG locus is primed for activation in the progenitor state by a highly connected enhancer community, which gets further activated and interconnected during adipogenesis. By systematically deleting individual enhancers in the community and interrogating the effect on enhancer function, connectivity and gene expression, we reveal important, non-redundant and cooperative roles of many enhancers. We show that the promoter-proximal enhancers and the downstream super-enhancer constituents cooperate in cis at early time points of differentiation, whereas at later timepoints PPARγ feedback-activates its own expression. Top-scoring non-coding cardiometabolic variants predicted to affect PPARG2 expression map to key enhancers in the community, indicating that regulation via these enhancers is important for human physiology.
Year:
2025
Adaptive thermogenesis in brown adipose tissue is regulated by PPARGC1A (PGC-1α), which could be affected by common polymorphism (rs8192678, Gly482Ser) that associates with metabolic disorders. We used CRISPR-Cas9 in immortalized human brown adipocyte cell line to edit the rs8192678 locus to evaluate the allele-dependent effects on cold response of brown adipocytes. In both 482Ser- and 482Gly-edited brown adipocytes, UCP1 expression increased after 6-hour cold exposure, but the increase was less pronounced in 482Gly cells, which also had lower mitochondrial activity. Furthermore, 482Gly PGC-1α had an almost two-fold longer half-life at 37°C, and four-fold longer half-life at 32°C, compared with the 482Ser variant. Despite the longer half-life, the 482Gly PGC-1α had lower activity, and was more prone to be retained in the cytoplasm after cold exposure. Our experimental data support gene x environment interactions between Gly482Ser and cold exposure in human brown adipocytes. These data support a novel molecular basis for the epidemiological observations that link the Gly482Ser polymorphism with obesity and related metabolic disorders.
Year:
2024
Overall adiposity and body fat distribution are heritable traits associated with altered risk of cardiometabolic disease and mortality. Performing rare variant (minor allele frequency<1%) association testing using exome-sequencing data from 402,375 participants in the UK Biobank (UKB) for nine overall and tissue-specific fat distribution traits, we identified 19 genes where putatively damaging rare variation associated with at least one trait (Bonferroni-adjusted P <1.58×10 -7 ) and 50 additional genes at FDR≤1% ( P ≤4.37×10 -5 ). These 69 genes exhibited significantly higher (one-sided t -test P =3.58×10 -18 ) common variant prioritisation scores than genes not significantly enriched for rare putatively damaging variation, with evidence of monotonic allelic series (dose-response relationships) among ultra-rare variants (minor allele count≤10) in 22 genes. Combining rare and common variation evidence, allelic series and longitudinal analysis, we selected 14 genes for CRISPR knockdown in human white adipose tissue cell lines. In three previously uncharacterised target genes, knockdown increased (two-sided t -test P <0.05) lipid accumulation, a cellular phenotype relevant for fat mass traits, compared to Cas9-empty negative controls: COL5A3 (fold change [FC]=1.72, P =0.0028), EXOC7 (FC=1.35, P =0.0096), and TRIP10 (FC=1.39, P =0.0157); furthermore, knockdown of PPARG (FC=0.25, P =5.52×10 -7 ) and SLTM (FC=0.51, P =1.91×10 -4 ) resulted in reduced lipid accumulation. Integrating across population-based genetic and in vitro functional evidence, we highlight therapeutic avenues for altering obesity and body fat distribution by modulating lipid accumulation.
Year:
2024
Collaborators (26)
Cecilia Lindgren
Steering Group Member
University of Oxford
Simon Georg Pfisterer
University of Helsinki
Frederik Heymann Lassen
Research Scholar
Broad Institute
Craig Glastonbury
Research Group Leader
Human Technopole
Susanne Mandrup
Professor at University of Southern Denmark
University of Southern Denmark
Robert Hegele
Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function
Western University
Paul Franks
Professor
Lund University Medical Faculty Foundation
Kenneth Matreyek
Assistant Professor
Case Western Reserve University
Ruth Loos
The Charles Bronfman Professor in Personalized Medicine
Københavns Universitet
Mafalda Bourbon
Invited Professor
Faculty of Medicine, University of Lisbon
Charles B. Epstein
Broad Institute
Jesper Grud Skat Madsen
Assistant Professor of Computational Biology
University of Southern Denmark
Megan Lancaster
Assistant Professor
Ohio State University
Andrew Glazer
Assistant Professor
Vanderbilt University Medical Center
Anke Husmann
Assistant Research Professor
University of Cambridge
Peter Spégel
Ass Prof
Lund University
Andrea Johanna Manrique Rincón
Staff Scientist
Wellcome Sanger Institute
Alexander Rauch
Associate Professor
University of Southern Denmark
Daniel Esteban Coral Candelo
Lund University
María José Romero Lado
University of Copenhagen
Frederick Roth
Professor and Chair
University of Pittsburgh
Elena Navarro-Guerrero
Head of Functional Genomics
University of Oxford
Gosia Trynka
Science Director and Immune Genomics Group Leader
Wellcome Sanger Institute
Douglas Fowler
Professor
University of Washington
Calum MacRae
Professor
Harvard University
Tuomas Kilpeläinen
Assistant professor
Københavns Universitet
Make your next move.
Prepare your application
Review drafts before you send them.